Ayala Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kenneth A. Berlin
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9 Deer Park Drive Monmouth Junction NJ United States of America 08852
- IPO Date
- May 8, 2020
- CIK
- 0001100397
- Website
- ayalapharma.com
- Similar Companies
- Business
- Ayala Pharmaceuticals, Inc. (Ticker: ADXS) is a clinical-stage biopharmaceutical company primarily engaged in developing novel immunotherapies targeting cancer and infectious diseases. The company focuses on the design, manufacture, and commercialization of therapeutic vaccines and immunotherapies aimed at enhancing the immune system’s ability to fight diseased cells. Its core product pipeline includes ADXS-NEO, ADXS-HOT, and other Listeria-based immunotherapies for oncology indications such as cervical cancer, head and neck cancer, and HPV-related malignancies. Ayala Pharmaceuticals provides investigational biologic agents and related clinical development services targeted at oncologists and healthcare professionals globally. Founded in 2004 and headquartered in San Diego, California, Ayala Pharmaceuticals operates in the biotechnology and healthcare sectors with research, development, and commercialization activities primarily in the United States and select international markets. The company’s platform leverages proprietary Listeria monocytogenes-based technology to stimulate durable immune responses. In recent developments over the last 1-2 years, Ayala Pharmaceuticals has advanced its clinical pipeline with new trials and expanded strategic collaborations in immuno-oncology. It has focused on broadening indications for its lead therapeutic candidates and initiated partnerships to enhance clinical development and market reach. The company continues to build on its innovative pipeline by progressing multiple Phase 2 and Phase 3 trials, reflecting a strategic shift toward late-stage development and potential commercial readiness. Overall, Ayala Pharmaceuticals combines proprietary immunotherapy technology platforms with clinical and regulatory expertise to address significant unmet needs in oncology and infectious diseases, aiming for global impacts in cancer treatment. It remains publicly traded under the ticker ADXS, maintaining its operational and research headquarters in San Diego. This description integrates core products and services with the latest company advancements and contextual business information as typically found in financial data provider profiles.
Aadi Bioscience (NASDAQ:AADI) and Ayala Pharmaceuticals (NASDAQ:ADXS) Head to Head Analysis
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS)
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
3 Hot Penny Stocks That Retail Traders Are Watching Right Now
Top Penny Stocks to Buy From TikTok? 3 That Investors Are Watching
6 of the Hottest Stocks to Pick Up for Less Than $1
Best Penny Stocks to Buy Next Month? 3 You Need to Know About
Top Trending Penny Stocks to Watch Next Month
3 Trending Penny Stocks For Your Small-Caps Watchlist Right Now